logo
As nicotine pouches' popularity soars, they're also responsible for more poisonings in young kids, study finds

As nicotine pouches' popularity soars, they're also responsible for more poisonings in young kids, study finds

CNN18 hours ago
Children's healthFacebookTweetLink
Follow
Nicotine pouches are a fast-growing source of nicotine poisoning in young children, according to a new study.
Researchers at Nationwide Children's Hospital in Ohio analyzed more than a decade's worth of data, examining over 134,000 cases of children under 6 who accidentally ingested nicotine through products like vapes, gums, and lozenges. Most types of exposures fell after 2016. But one delivery method — nicotine pouches — shot up, rising more than 760% between 2020 and 2023.
'It's a high-concentration nicotine product, and it tastes good,' said Dr. Natalie Rine, director of the Central Ohio Poison Center at Nationwide Children's Hospital and co-author of the study, published Monday in the journal Pediatrics. 'There's nothing telling the kid, 'this is bad, you should spit it out' … and that's where you get into trouble.'
The miniature white packets that users tuck between their lip and gum hit US shelves in 2014. They don't contain tobacco but are instead filled with nicotine, either synthetically or naturally derived, along with flavorings and sweeteners.
The discreet, sweet and smokeless nature of nicotine pouches has raised concerns among public health advocates, who are closely watching their rising popularity among teens and young adults. They've become the second most-used nicotine product among young people, according to the US Centers for Disease Control and Prevention. The National Youth Tobacco Survey found that nicotine pouch use among teens doubled between 2021 and 2024.
Still, the overall user base remains small. Just 0.5% of Americans use nicotine pouches, compared with 9% who smoke cigarettes and 3% who vape or use e-cigarettes, according to US Census Bureau data.
Levels of nicotine in pouches can vary from 3 to 12 milligrams per pouch. At their lowest doses, they deliver more of the stimulant than a cigarette, and even small amounts of nicotine can be dangerous for small children. Ingesting just 1 to 2 milligrams — less than what's inside a single regular-strength pouch — can cause nausea, vomiting and tremors, among other serious symptoms, according to the National Library of Medicine.
The study found that nicotine pouches were associated with a 150% greater risk of serious medical effects and were twice as likely to lead to hospitalization than other smokeless nicotine products swallowed by children, like gums, lozenges, e-liquids, tablets and powders.
Although the vast majority of pediatric nicotine ingestions resulted in little to no harm, more than 1,600 children had serious medical outcomes, the study found. Two children died after ingesting liquid nicotine.
Rine recommends that parents avoid using nicotine pouches in front of children to keep them from imitating potentially risky adult behaviors. She also suggests keeping nicotine products physically out of kids' reach and to have conversations with other caretakers, like babysitters and extended family, about doing the same.
If a child may have ingested a nicotine pouch, Rine says, the best first step is to call Poison Control at 1-800-222-1222. Trained staff can guide caregivers based on a child's symptoms and help them decide if emergency care is needed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Yahoo

time22 minutes ago

  • Yahoo

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the Company will conduct a gap analysis of its existing data prior to submitting a Minor Use Minor Species (MUMS) designation request to the United States Food and Drug Administration (FDA) for tafenoquine for the treatment of acute canine babesiosis. The submission will be based on results of three clinical efficacy studies that evaluated ARAKODA® (tafenoquine) for canine babesiosis, and existing canine safety data and chemistry manufacturing and controls (CMC) data for tafenoquine generated through the clinical development of ARAKODA for malaria. The clinical efficacy studies involved experimental Babesia infections and dogs diagnosed with naturally acquired Babesia infection in veterinary clinics. One of the studies was company-sponsored and conducted at North Carolina State University. Collectively, the studies showed that tafenoquine, administered as ARAKODA tablets, was well tolerated and appeared to facilitate recovery from acute infection. Every year in the United States, several hundred to several thousand cases of canine babesiosis are seen. It is an emerging tick-borne illness carried by the same tick vector as Lyme Disease. No FDA-approved oral treatment for canine babesiosis exists, and currently available treatments carry significant toxicity risk or the propensity to generate drug resistance. 'Data from the canine babesiosis studies are impactful when viewed in the larger context of the ground-breaking human babesiosis research we are now sponsoring,' said Chief Executive Officer of 60 Degrees Pharmaceuticals, Geoff Dow. 'The positive findings of the canine babesiosis study are in line with our earlier findings that tafenoquine could be effective against babesiosis in humans.' About ARAKODA® (tafenoquine)Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. Tafenoquine has not been proven to be effective for treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for such an indication. ARAKODA® (tafenoquine) Important Safety Information ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. Contraindications ARAKODA® should not be administered to: Glucose-6-phosphate dehydrogenase ('G6PD') deficiency or unknown G6PD status; Breastfeeding by a lactating woman when the infant is found to be G6PD deficient or if G6PD status is unknown; Patients with a history of psychotic disorders or current psychotic symptoms; or Known hypersensitivity reactions to tafenoquine, other 8-aminoquinolines, or any component of ARAKODA®. Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant's G6PD status before breastfeeding begins. Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur. Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible. Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy. Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration. Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety. Drug Interactions Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters. Use in Specific Populations Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or The full prescribing information of ARAKODA® is located here. About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking StatementsThis press release may contain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ('SEC'), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts:Sheila A. BurkeSheilaBurke-consultant@ 667-6330 Investor Contact:Patrick Gaynespatrickgaynes@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'
New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'

Yahoo

time36 minutes ago

  • Yahoo

New Jersey woman nearly dies after taking dangerous amount of popular supplement: ‘I was very, very, very scared'

A New Jersey woman says she almost died after taking daily turmeric pills, a popular supplement found in grocery stores. Katie Mohan, a 57-year-old from Morristown, told she sustained liver damage after taking daily pills of turmeric, a yellow spice widely used for its antioxidant and anti-inflammatory properties. Mohan said her first symptoms included fatigue, nausea, stomach pain and yellowing eyes, which are a sign of jaundice. Mohan first saw her doctor in April, but the scans and tests ordered came back normal. Her symptoms continued to get worse until June, when Mohan read an NBC News story about a man with similar symptoms who found out he had a drug-induced liver injury after taking turmeric daily. 'I threw [the supplements] out, and I said to myself, 'I'm wondering if this is what's causing my symptoms,'' Mohan told Mohan bought the turmeric pills, which were manufactured by YouTheory, at Costco, reports. The product states the daily dose is three pills containing 2,250 milligrams, Mohan said, which is over the World Health Organization's recommendation of up to 3 milligrams per kilogram of body weight per day. A New Jersey woman says she damaged her liver by taking daily turmeric supplements (Getty Images) After reading the NBC News article, Mohan went to urgent care. From there, she was admitted to Morristown Medical Center, where doctors found that she had severe liver damage. She was treated with an antiviral IV drip, but her skin was still yellowing. Mohan recalled thinking: 'Am I going to need a liver transplant? Am I going to die?' 'I was very, very, very scared,' she added. That's when she was transferred to NYU Langone in New York. There, her doctor found 'evidence of acute hepatitis, impending liver failure and potential transplant evaluation.' 'She was really very sick,' Dr. Nikolaos Pyrsopoulos, told 'Her liver numbers were 60 to 70 times above the normal limit. And she was very yellow.' Mohan said Pyrsopoulos confirmed her fears that the turmeric caused her symptoms. Katie Mohan said she was worried she would need a liver transplant after taking too much turmeric (Getty Images) 'He's like, 'You essentially poisoned the liver with the turmeric,'' she said. 'It was the dose combined with the fact that it had that black pepper in it.' Pyrsopoulos told that his hospital sees three to four liver transplants per year related to turmeric poisoning. Mohan has since been discharged and says her liver enzyme levels are still elevated, but they're continuing to fall and her symptoms have completely disappeared. Mohan has since reported the supplements to the Food and Drug Administration. The Independent has contacted Costco and YouTheory for comment.

New York official again rebuffs Texas judgment against doctor over abortion pills
New York official again rebuffs Texas judgment against doctor over abortion pills

Yahoo

time36 minutes ago

  • Yahoo

New York official again rebuffs Texas judgment against doctor over abortion pills

By Daniel Wiessner (Reuters) -A county official in New York on Monday rejected for a second time efforts by Texas to enforce a $100,000 judgment against a New York doctor accused of violating Texas' ban on abortion by sending abortion pills to the state, further escalating an unprecedented interstate conflict. Acting Ulster County Clerk Taylor Bruck in a letter to the office of Republican Texas Attorney General Ken Paxton doubled down on his March finding that New York's so-called shield law precludes the enforcement of other states' abortion bans against New Yorkers. Paxton's office last week had asked Bruck to reconsider, arguing that he had a legal duty to enforce the judgment against New Paltz, New York-based doctor Margaret Carpenter. Bruck on Monday said Paxton's office had not presented any new information. "While I'm not entirely sure how things work in Texas, here in New York, a rejection means the matter is closed," wrote Bruck, who is running for county clerk as a Democrat. Paxton's office and the Abortion Coalition for Telemedicine, a group co-founded by Carpenter, did not immediately respond to requests for comment. New York Governor Kathy Hochul, a Democrat who championed the passage of the shield law earlier this year, praised Bruck for "defending the freedom generations of women fought to secure." "Our response to (Texas') baseless claim is clear: no way in hell. New York won't be bullied," Hochul said in a statement. Medication abortion accounts for more than half of U.S. abortions. It has drawn increasing attention since the U.S. Supreme Court's 2022 decision allowing states to ban abortion, which more than 20 states, including Texas, have done. A judge in Collin County, Texas, entered a default judgment against Carpenter in February after she failed to respond to the state's civil lawsuit alleging she illegally prescribed mifepristone and misoprostol, the two drugs used in medication abortion, to a Texas woman via telemedicine. Carpenter has also been indicted by a Louisiana grand jury for prescribing an abortion pill that was taken by a teenager there, in what appeared to be the first time a state criminally charged a doctor in another state for prescribing abortion drugs. Hochul in February rejected Louisiana's request to extradite Carpenter there.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store